Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07219719

Temporal Interference for Thalamocortical Activity and Network Modulation

The goal of this clinical trial is to find out whether a type of electrical brain stimulation, called temporal interference stimulation, can temporarily change the way different parts of the brain communicate with each other.

Participants will:

* Complete two stimulation phases - overnight and during wakefulness * Undergo two MRIs per study phase

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

University of Wisconsin - Madison

Madison, Wisconsin, 53705, United States

Location status: Recruiting

Location contact

Sean Prahl

CONTACT

[email protected]

262-395-8675

About this study

This study will evaluate the effectiveness of personalized thalamic temporal interference transcranial electrical stimulation (TI-TES) to modulate thalamocortical activity and connectivity in healthy adults. Using a within-subject, counterbalanced crossover design, participants will complete two stimulation phases: (1) repeated overnight TI-TES or sham stimulation during NREM sleep and (2) repeated during quiet wakefulness. Each phase consists of two sessions. Phases are separated by a ≥4-week washout. Resting-state functional magnetic resonance imaging (fMRI) will be acquired before and after each phase to assess sustained changes in thalamocortical functional connectivity, with high-density EEG providing secondary measures of brain-state-specific oscillatory modulation (sigma/spindles in sleep, alpha in wake).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18-50
  • Medically healthy
  • U.S. citizen or holding permanent resident status
  • English-speaking

Exclusion criteria

  • Any current or past history of neurological disorders or acquired neurological disease (e.g. stroke, traumatic brain injury), including intracranial lesions (including clinically significant findings identified in first MRI)
  • History of inpatient psychiatric hospitalization
  • History of head trauma resulting in prolonged loss of consciousness; or a history of greater than 3 grade I concussions
  • Current history of poorly controlled headaches including intractable or poorly controlled migraines
  • Any systemic illness or unstable medical condition that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)
  • History of seizures, diagnosis of epilepsy, history of abnormal (epileptiform) EEG, or family history of treatment resistant epilepsy except for a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist
  • Possible pregnancy or plan to become pregnant in the next 6 months (self reported)
  • Any metal in the head
  • Any medical devices or implants (i.e. cardiac pacemaker, medication infusion pump, cochlear implant, vagal nerve stimulator)
  • Dental implants
  • Permanent retainers
  • Any hair braid, dreadlocks, hair pieces, or extensions which cannot be taken out before the study sessions
  • Any head coverings or headdress that participant feels uncomfortable removing for the purposes of study sessions
  • Any medication that may alter seizure threshold taken during the study i.e., Attention-deficit/hyperactivity disorder (ADHD) stimulants (Adderall, amphetamine); Tricyclic/atypical antidepressants (amitriptyline, doxepin, imipramine, maprotiline, nortriptyline, bupropion); SSRIs (Escitalopram, Fluoxetine, Sertraline); Antipsychotics (chlorpromazine, clozapine), Bronchodilators (theophylline, aminophylline); Antibiotics (fluoroquinolones, imipenem, penicillin, cephalosporins, metronidazole, isoniazid); Antivirals (valacyclovir, ritonavir); over the counter antihistamines (diphenhydramine, Benadryl); Estradiol-based birth control
  • Claustrophobia (a fear of small or closed places)
  • Back problems that would prevent lying flat for up to two hours
  • Regular night-shift work (second or third shift)
  • Sleep apnea or other sleep disorder (self-reported)

Treatment and study plan

Temporal Interference Transcranial electrical stimulation (TI-TES)

Device

TI-TES uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TI-TES.

Sham stimulation

Device

Sham (ramp only) stimulation will briefly ramp up and down at the beginning and end of each stimulation train, without delivering continuous stimulation throughout.

Primary outcomes

  1. Change in thalamocortical functional connectivity (FC): resting state fMRI

    Time frame: Pre- to post-intervention, up to 2 weeks

    Resting-state fMRI will be used to assess changes in thalamocortical functional connectivity before and after repeated thalamic TI-TES delivered during NREM sleep and quiet wakefulness.

  2. Difference in magnitude of FC changes between sleep and wake

    Time frame: 8 weeks

    The magnitude of FC changes between sleep and wake stimulation phases will be evaluated.

  3. Difference in spatial distribution of FC changes between sleep and wake

    Time frame: 8 weeks

    The spatial distribution of FC changes between sleep and wake stimulation phases will be evaluated.

Secondary outcomes

  1. Change in sigma-band power (EEG, sleep phase)

    Time frame: During and after each overnight stimulation session, up to 1 week

    Sigma band power will be measured with high density EEG (hdEEG) during stimulation, and will be analyzed to quantify stimulation-related changes in sigma-band power during NREM sleep.

  2. Change in alpha band power during wake stimulation sessions

    Time frame: During and after each wake stimulation session, up to 1 week

    Alpha band power will be measured with hdEEG during stimulation, and will be analyzed to quantify stimulation-related changes in alpha-band power during quiet wakefulness stimulation.

  3. Return to baseline thalamocortical FC

    Time frame: 8 weeks

    After the ≥4-week washout, thalamocortical FC will be assessed by resting-state fMRI prior to the second stimulation phase.

  4. Change in structural thalamocortical connectivity

    Time frame: Pre- to post-intervention, up to 2 weeks

    Will be measured using diffusion-weighted imaging (DWI) in each phase.

  5. Change in mood

    Time frame: Baseline to 12 weeks

    Mood will be scored using Positive and Negative Affect Schedule (PANAS). PANAS is a 20 item questionnaire, each item is rated on a 5-point scale, with 1 = "Very slightly or not at all" and 5 = "Extremely". To score PANAS, sum the scores for the 10 Positive Affect (PA) items and the 10 Negative Affect (NA) items separately on the 5-point scale. Higher scores for PA indicate a greater degree of positive emotion, while higher scores for NA indicate more negative emotion, with both scales ranging from 10 (low affect) to 50 (high affect).

  6. Change in Boston Cognitive Assessment (BoCA)

    Time frame: Baseline to 12 weeks

    BoCA™ evaluates eight cognitive domains using randomized, non-repeating tasks to minimize practice effects. The total maximum score is 30. Higher scores indicate better cognitive performance.

  7. Change in spindle characteristics: Density

    Time frame: Up to 1 week

    HdEEG will be analyzed to assess stimulation-related changes in spindle density during NREM sleep.

  8. Change in spindle characteristics: Amplitude

    Time frame: Up to 1 week

    HdEEG will be analyzed to assess stimulation-related changes in spindle amplitude during NREM sleep.

  9. Change in spindle characteristics: Duration

    Time frame: Up to 1 week

    HdEEG will be analyzed to assess stimulation-related changes in spindle duration during NREM sleep.

Study contacts

Contact information is provided by the study sponsor or research team.

Larissa Albantakis, PhD

CONTACT

Sean Prahl

CONTACT

[email protected]

262-395-8675

Sponsors and collaborators

Lead sponsor

University of Wisconsin, Madison

Other

Registry information

Acronym: TITAN

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Oct 22, 2025
Registry last updated
Apr 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.